Delix News

Check out our recent news

Screenshot of the hero banner taken from New York Times article: "Taking the Magic Out of Magic Mushrooms"

sept 2022

Delix Therapeutics Expands World-Class Team with First Head of R&D

sept 2022

Nature Biotechnology Selects Delix Therapeutics as a Leading Biotech Start-Up

sept 2022

Nature Biotechnology’s academic spinouts 2021

aug 2022

Get Ready for the Magic Mushroom Pill

july 2022

Accessibility Is Key for the Psychedelic Revolution

mar 2022

Drug companies are investing big in psychedelics, but can they engineer out the trip?

jan 2022

The Future of Psychedelic Medicine Will Be Drugs You’ve Never Heard Of

jan 2022

Delix Therapeutics Closes $30 Million Convertible Note Financing, Enters $10 Million Strategic Credit Facility Option in Partnership with Comerica Bank

dec 2021

Delix Therapeutics Partners with the National Institute on Drug Abuse (NIDA) to Advance Research on Non-Hallucinogenic Therapies to Treat Substance Use Disorders

oct 2021

Delix Therapeutics Announces Appointment of Dr. John Krystal to Scientific & Strategic Advisory Board

oct 2021

Delix Therapeutics Named One of Fierce Biotech’s “Fierce 15” Companies of 2021

sept 2021

Delix Therapeutics Closes $70 Million Series A Financing to Advance Pipeline of Novel Psychoplastogen Therapeutics to Treat Brain Disorders

aug 2021

Delix Therapeutics Continues Rapid Growth with Appointment of Chief Medical Officer

july 2021

Delix Therapeutics Expands Executive Leadership Team

june 2021

Delix Therapeutics Announces Scientific and Strategic Advisory Board Appointments

may 2021

Delix Therapeutics Retains KSCA Strategic Communications

apr 2021

Delix Therapeutics Co-Founder Publishes Groundbreaking Study Demonstrating Therapeutic Potential for a Psychedelic Analog -- Without Hallucinogenic Effects

mar 2021

Delix Therapeutics Names Mark Rus as Chief Executive Officer